Press releases

^{Some non-regulatory announcements are only available in English. All announcements required under applicable law, regulation or code are available in English and Swedish.}

YearType

2025

10 Oct 2025, 10:00

Data from GNT-018-IDES trial supports feasibility of imlifidase as pretreatment in gene therapy treatment for patients with Crigler–Najjar syndrome who are immune to AAV

Results presented today at ESGCT 2025

8 Oct 2025, 16:00

Hansa Biopharma to host Q3 2025 interim results conference call

7 Oct 2025, 17:00

Hansa Biopharma participating in Optimum’s 17th Annual Healthcare Investor Conference and at Nordic Life Science Days 2025

2 Oct 2025, 08:30 | Regulatory

Hansa Biopharma publishes disclosure document for admission to trading of shares on Nasdaq Stockholm

2 Oct 2025, 00:15 | Regulatory

Hansa Biopharma has carried out a directed share issue of 17 million shares, raising proceeds of approximately USD 71 million

1 Oct 2025, 17:31 | Regulatory

Hansa Biopharma intends to carry out a directed share issue of approximately USD 60 million

26 Sep 2025, 18:50

Genethon to present preliminary efficacy and safety data from Phase 2 trial of imlifidase as a pre-treatment to GNT-0003 at ESGCT congress 2025

24 Sep 2025, 18:21 | Regulatory

Imlifidase successfully meets primary endpoint in pivotal US Phase 3 ConfIdeS trial in kidney transplantation

· At 12 months, mean eGFR was 51.5 mL/min/1.73m[2] in the imlifidase arm versus 19.3 mL/min/1.73m[2] in the control arm with a statistically significant and clinically meaningful difference of 32.2 mL/min/1.73m[2] ( p<0.0001)
· Imlifidase was generally well tolerated with a safety profile consistent with previous clinical trial experience
· Submission of a Biolo…

E-mail

Press releases

2025

Sign up to receive updates on the latest company news and filings

Choose type